I don't have that number handy, but I will share a couple of examples that might be helpful in your deliberations around Ozempic.
It's obviously not covered under the proposed list of medications. It's widely used. We've recently had a shortage of Ozempic across the country, and my association works very regularly to address shortages that are a growing problem in the country. When we talk about pharmacare, it's not just about the cost of drugs or the services that are being offered; if that medication is not available in the country, no amount of coverage is going to help that.
One thing that we've noted is that the number of available medications in each drug class can decrease significantly, depending on how many companies are in the market, and we are most vulnerable to drug shortages if only one or two manufacturers are producing a particular drug.
Let's say that there's a national disaster in one country that's producing some of the API, and the one company there can't produce that drug, and the other companies aren't able to readily increase their production. In cases like that, we've really suffered significantly with many drug shortages, so I think there's a really complicated ecosystem that this pharmacare approach needs to also recognize.